- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06906341
진보 된, 상피 난소, 1 차 복막 또는 나팔관 암에서 NAB- 파클리탁셀 및 베바 시주 맙과의 관련성
진보 된, 상피 난소, 1 차 복막 또는 나팔관 암 (Bella)에서 NAB- 파클리탁셀 및 베바 시주 맙과의 조합 된 2 상 분리 연구
This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.
연구 개요
상태
상세 설명
This study is designed with the goal to add additional arms as new treatments become available. All arms will follow an independent and parallel design.
For Arms A and B, study treatment will comprise relacorilant combined with nab-paclitaxel, and bevacizumab and will begin on Cycle 1 Day 1 (C1D1). Each patient will receive relacorilant 150 mg administered orally under fed conditions, once daily for 3 consecutive days on the day before, the day of, and the day after nab-paclitaxel infusion (in Cycle 1 relacorilant is only given on 2 consecutive days, starting on C1D1), in combination with nab-paclitaxel (80 mg/m^2 intravenously [IV]) administered on Days 1, 8, and 15 of each 28-day cycle. Bevacizumab (10 mg/kg IV once every 2 weeks [Q2W]) will be administered on Days 1 and 15 of each 28-day cycle. Study treatment for Arm C will be similar to Arm A but does not include bevacizumab. Patients will receive treatment until they reach a protocol-defined event of progressive disease (PD), experience an unmanageable toxicity, or until other treatment discontinuation criteria are met.
연구 유형
등록 (추정된)
단계
- 2 단계
연락처 및 위치
연구 연락처
- 이름: Corcept Therapeutics
- 전화번호: 650-414-2314
- 이메일: corceptstudy557@corcept.com
연구 장소
-
-
Gangnam-gu
-
Seoul, Gangnam-gu, 대한민국, 06351
- 모병
- 396
-
-
Goyang-si
-
Gyeonggi-do, Goyang-si, 대한민국, 10408
- 모병
- 397
-
-
Jongno-gu
-
Seoul, Jongno-gu, 대한민국, 03080
- 모병
- 399
-
-
Seocho-gu
-
Seoul, Seocho-gu, 대한민국, 06591
- 모병
- 523
-
-
Seodaemun-gu
-
Seoul, Seodaemun-gu, 대한민국, 03722
- 모병
- 398
-
-
Songpa-gu
-
Seoul, Songpa-gu, 대한민국, 05505
- 모병
- 403
-
-
-
-
-
Aachen, 독일, 52074
- 모병
- 519
-
Berlin, 독일, 10117
- 모병
- 255
-
Kempten, 독일, 87439
- 모병
- 520
-
-
-
-
Alabama
-
Birmingham, Alabama, 미국, 35233
- 모병
- 004
-
-
California
-
Palo Alto, California, 미국, 94304
- 모병
- 150
-
San Francisco, California, 미국, 94109
- 모병
- 278
-
San Francisco, California, 미국, 94143
- 모병
- 014
-
-
Colorado
-
Aurora, Colorado, 미국, 80045
- 모병
- 032
-
-
Florida
-
Fort Myers, Florida, 미국, 33901
- 모병
- 544
-
Miami Beach, Florida, 미국, 33140
- 모병
- 335
-
West Palm Beach, Florida, 미국, 33041
- 모병
- 543
-
-
Illinois
-
Chicago, Illinois, 미국, 60637
- 모병
- 001
-
-
Minnesota
-
Minneapolis, Minnesota, 미국, 55404
- 모병
- 518
-
-
Missouri
-
Kansas City, Missouri, 미국, 64132
- 모병
- 334
-
St Louis, Missouri, 미국, 63110
- 모병
- 521
-
-
New Mexico
-
Albuquerque, New Mexico, 미국, 97102
- 모병
- 292
-
-
Ohio
-
Centerville, Ohio, 미국, 45459
- 모병
- 304
-
-
Oregon
-
Eugene, Oregon, 미국, 97401
- 모병
- 517
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, 미국, 15213
- 모병
- 127
-
-
Virginia
-
Fairfax, Virginia, 미국, 22031
- 모병
- 522
-
Norfolk, Virginia, 미국, 23502
- 모병
- 300
-
-
Wisconsin
-
Milwaukee, Wisconsin, 미국, 53226
- 모병
- 121
-
-
-
-
-
Brussels, 벨기에, 1200
- 모병
- 109
-
Charleroi, 벨기에, 6000
- 모병
- 326
-
Hasselt, 벨기에, 3500
- 모병
- 325
-
Leuven, 벨기에, 3000
- 모병
- 108
-
-
Belgium
-
Aalst, Belgium, 벨기에, 9300
- 모병
- 328
-
-
-
-
-
Badalona, 스페인, 08916
- 모병
- 349
-
Barcelona, 스페인, 08035
- 모병
- 115
-
Madrid, 스페인, 28034
- 모병
- 114
-
Valencia, 스페인, 46026
- 모병
- 330
-
Valencia, 스페인, 46010
- 모병
- 558
-
-
-
-
-
Catania, 이탈리아, 95126
- 모병
- 321
-
Milan, 이탈리아, 20141
- 모병
- 122
-
Milan, 이탈리아, 20159
- 모병
- 516
-
Pavia, 이탈리아, 27100
- 모병
- 295
-
Rome, 이탈리아, 00168
- 모병
- 124
-
Torino, 이탈리아, 10128
- 모병
- 293
-
Treviso, 이탈리아, 31100
- 모병
- 319
-
-
-
-
-
Gdynia, 폴란드, 81-519
- 모병
- 341
-
Siedlce, 폴란드, 08-MO
- 모병
- 329
-
-
-
-
-
Lille, 프랑스, 59000
- 모병
- 306
-
Nancy, 프랑스, 54100
- 모병
- 307
-
Nice, 프랑스, 06100
- 모병
- 310
-
Pierre-Bénite, 프랑스, 69495
- 모병
- 324
-
Plérin, 프랑스, 22190
- 모병
- 323
-
Toulouse, 프랑스, 31059
- 모병
- 308
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
Arms A and B
- Histologic diagnosis of epithelial ovarian, primary peritoneal, or fallopian-tube carcinoma
- Arm A Only: Platinum-resistant disease
- Arm B Only: Platinum-sensitive disease who had progression while receiving treatment with a poly(ADP-ribose) polymerase (PARP) inhibitor
- Life expectancy of ≥3 months
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Able to swallow and retain oral medication
- 1 to 3 lines of prior systemic anticancer therapy
- Adequate organ function
- Negative pregnancy test for patients of childbearing potential
Arm C
- Stage III or IV, recurrent, or metastatic endometrial cancer
- Life expectancy of ≥3 months
- ECOG performance status of 0 or 1
- Able to swallow and retain oral medication
- Prior treatment with a platinum agent and an approved anti-Programmed Cell Death Ligand 1 (PD[L]1) antibody
- 1 to 2 lines of prior systemic anticancer therapy for endometrial cancer
- Must consent to provide an available formalin-fixed paraffin-embedded (FFPE) tumor tissue block or recently cut sections
- Adequate organ function
- Negative pregnancy test for patients of childbearing potential
Exclusion Criteria:
Arm A and B
- Arm A Only: Has progressed while receiving weekly paclitaxel or nab-paclitaxel
- Prior enrollment in a clinical trial of relacorilant
- Prior anticancer therapy related toxicities not resolved to grade ≤1
- Any surgery within 4 weeks prior to enrollment
- Wide-field radiation to more than 25% of marrow-bearing areas
- Medical conditions requiring chronic or frequent treatment with corticosteroids
- Concurrent treatment with mifepristone or other glucocorticoid receptor modulators
- Peripheral neuropathy from any cause >Grade 1
- Hypertension: ≥150 mm Hg systolic or ≥100 mm Hg diastolic
- Uncontrolled condition(s) which, may confound the results of the trial or interfere with the patient's safety or participation
- Bowel obstruction ≤12 weeks prior to study entry
- Ascites or pleural effusions requiring therapeutic paracentesis
- Untreated or symptomatic central nervous system metastases
- History of other malignancy within 3 years prior to enrollment
- Has received a live vaccine within 30 days prior to the study start date
Arm C
- Has progressed while receiving weekly paclitaxel or nab-paclitaxel
- Prior enrollment in a clinical trial of relacorilant
- Prior anticancer therapy related toxicities not resolved to grade ≤1
- Any surgery within 4 weeks prior to enrollment
- Wide-field radiation to more than 25% of marrow-bearing areas
- Medical conditions requiring chronic or frequent treatment with corticosteroids
- Concurrent treatment with mifepristone or other glucocorticoid receptor modulators
- Peripheral neuropathy from any cause >Grade 1
- Uncontrolled condition(s) which, may confound the results of the trial or interfere with the patient's safety or participation
- Bowel obstruction ≤12 weeks prior to study entry
- Ascites or pleural effusions requiring therapeutic paracentesis
- History of other malignancy within 3 years prior to enrollment
- Has received a live vaccine within 30 days prior to the study start date
- Patients with central nervous system metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids for this indication for at least 4 weeks before starting treatment in this study.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Arm A: Relacorilant in Combination with Nab-paclitaxel and Bevacizumab
In Arm A, patients with platinum-resistant ovarian cancer will receive the combination of relacorilant with nab-paclitaxel and bevacizumab. |
Relacorilant is administered under fed conditions as capsules for oral dosing on the day before, the day of, and the day after nab-paclitaxel infusion.
다른 이름들:
Nab-paclitaxel is administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle. Bevacizumab is administered as IV infusion on Days 1 and 15. |
|
실험적: Arm B: Relacorilant in Combination with Nab-Paclitaxel and Bevacizumab
In Arm B, patients with platinum-sensitive ovarian cancer who have progressed while receiving treatment with a polymerase inhibitor will receive relacorilant in combination with nab-paclitaxel and bevacizumab. |
Relacorilant is administered under fed conditions as capsules for oral dosing on the day before, the day of, and the day after nab-paclitaxel infusion.
다른 이름들:
Nab-paclitaxel is administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle. Bevacizumab is administered as IV infusion on Days 1 and 15. |
|
실험적: Arm C: Relacorilant in Combination with Nab-Paclitaxel
In Arm C, patients with previously-treated advanced, recurrent, or metastatic endometrial cancer will receive relacorilant in combination with nab-paclitaxel. |
Relacorilant is administered under fed conditions as capsules for oral dosing on the day before, the day of, and the day after nab-paclitaxel infusion.
다른 이름들:
Nab-paclitaxel is administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Progression-Free Survival (PFS)
기간: Date of first dose until PD or death, up to 18 months
|
To evaluate PFS as the time from enrollment until first documented progressive disease (PD) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 as determined by the Investigator, or death due to any cause, whichever occurs first. |
Date of first dose until PD or death, up to 18 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
하나 이상의 부작용이있는 환자의 수
기간: 마지막 복용 후 최대 30 일의 첫 번째 복용량 날짜
|
마지막 복용 후 최대 30 일의 첫 번째 복용량 날짜
|
|
|
Objective Response Rate (ORR)
기간: Date of first dose until PD or death, up to 18 months
|
To evaluate the proportion of patients with measurable disease at Baseline who attain complete response (CR) or partial response (PR) by RECIST version 1.1. |
Date of first dose until PD or death, up to 18 months
|
|
Best Overall Response Rate (BOR)
기간: Date of first dose until PD or death, up to 18 months
|
To evaluate the BOR by RECIST version 1.1 recorded from the date of enrollment until PD or death. |
Date of first dose until PD or death, up to 18 months
|
|
Duration of Response (DOR)
기간: Time of first objective response until PD or death, up to 18 months
|
To evaluate DOR as the time from the first CR or PR to first objectively documented PD or death, whichever comes first. |
Time of first objective response until PD or death, up to 18 months
|
|
Clinical Benefit Rate (CBR)
기간: Week 24
|
To evaluate CBR as the proportion of patients who attain CR, PR, or stable disease (SD) at Week 24 as per RECIST version 1.1. |
Week 24
|
|
Overall Survival (OS)
기간: Date of first dose up to 6, 12, and 18 months
|
To evaluate the probability of OS survival at 6, 12, and 18 months. |
Date of first dose up to 6, 12, and 18 months
|
|
Area under the plasma concentration-time curve (AUC) of relacorilant
기간: On Cycle 1 Day 8 (each cycle is 28 days)
|
To estimate exposure of relacorilant. This outcome applies to Arms B and C only. |
On Cycle 1 Day 8 (each cycle is 28 days)
|
|
Maximum plasma concentration (Cmax) of relacorilant
기간: On Cycle1 Day 8 (each cycle is 28 days)
|
To estimate exposure of relacorilant. This outcome applies to Arms B and C only. |
On Cycle1 Day 8 (each cycle is 28 days)
|
|
Trough plasma concentrations (Cmin) of relacorilant
기간: On Cycle 2 Day 8 through the last cycle (up to 12 cycles, each cycle is 28 days)
|
To estimate exposure of relacorilant. This outcome applies to Arms B and C only. |
On Cycle 2 Day 8 through the last cycle (up to 12 cycles, each cycle is 28 days)
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Danny Nguyen, MD, Corcept Therapeutics
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
- 비뇨생식기 질환
- 생식기 질환
- 내분비계 질환
- 비뇨생식기 신생물
- 여성 비뇨 생식기 질환
- 여성 비뇨 생식기 질환 및 임신 합병증
- 소화계 신생물
- 소화기계 질환
- 자궁 질환
- 생식기 질환, 여성
- 내분비샘 신생물
- 부속기 질환
- 생식선 장애
- 자궁 신생물
- 복막 질환
- 복부 신생물
- 신생물
- 난소 신생물
- 자궁내막 신생물
- 생식기 신생물, 여성
- 복막 신생물
- 나팔관 신생물
- 부위별 신생물
- 난소 질환
- 나팔관 질환
- 아미노산, 펩티드 및 단백질
- 단백질
- 항체, 모노클로 날, 인간화
- 항체, 모노클로 날
- 항체
- 면역 글로불린
- 면역 단백질
- 혈액 단백질
- 혈청 글로불린
- 글로불린
- 베바시주맙
- 130nm 알부민 결합 파클리탁셀
- relacorilant
기타 연구 ID 번호
- CORT125134-557
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .